Price
No data yet.
Social Signal Score
Revenue
$485.4K+175.36%Company Profile
- CEO
- Larry Powalisz
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Employees
- 3
- Beta
- -8.23
- Country
- US
Financials
ADIA has only 2 quarterly periods on file — the charts below show the full history available.
Revenue
$485.4K+175.4%Net Income
$40.4KEBITDA
$59.2KFree Cash Flow
$-103.5KEPS (diluted)
$0.25Shares Outstanding (diluted)
161.4K+71.0%Operating Expenses
$134.7KCash & Debt
$128.1KRevenue by Segment (annual)
$291.9KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $700.5K | $-395.5K | $-4.23 |
| 2023 | $0.00 | $-0.75 | $-0.00 |
Valuation
ADIAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+25.00%Social Signal Score
Mentions (5)
- Newsnewsfilecorp.com·7d ago·Neutral
…ore options in cell count, format, and concentration for investigational studies. Winter Park, Florida--(Newsfile Corp. - September 29, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies, biologics, and physician-supervised investigational research, today announced that its laboratory subsidiary, Adia Labs LLC, has expanded its product portfolio with three new research-use offerings: Adia30M, AdiaClear, and AdiaEXO.
View source ↗ - Newsnewsfilecorp.com·14d ago·Neutral
… Exceeds $1.5 Million to Meet Rising Demand for the Company's Biological Products Winter Park, Florida--(Newsfile Corp. - September 22, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies, biologics, and physician-supervised investigational research, today announced that the estimated retail value of biologic inventory at its laboratory division, Adia Labs LLC, now exceeds $1.5 million, driven by accelerating demand for the Company's biologic produ…
View source ↗ - Newsnewsfilecorp.com·36d ago·Negative
…ersity into an intern-led content team across YouTube, Meta, TikTok, X, and LinkedIn Winter Park, Florida--(Newsfile Corp. - August 31, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies, biologics, and advanced clinical services, today announced that its introductory innovation session earlier this month at Full Sail University delivered exactly the spark the Company was looking for — and that Adia Med has already assembled a social media team of…
View source ↗ - Newsnewsfilecorp.com·43d ago·Negative
… Med Inc. Engages Lucosky Brookman LLP as Legal Counsel for Planned NASDAQ Uplisting Winter Park, Florida--(Newsfile Corp. - August 24, 2026) - Adia Med Inc. (OTCQB: ADIA) today announced that it has entered into an engagement letter with Lucosky Brookman LLP ("Lucosky Brookman") to act as legal counsel in connection with the Company's planned uplisting from the OTC Markets to the NASDAQ Capital Market. Lucosky Brookman LLP To view an enhanced version of this graphic, please visit: https://image…
View source ↗ - Newsnewsfilecorp.com·53d ago·Negative
…K Revenue, First Net Profit, and Nearly Matches Full-Year 2025 Revenue in First Half Winter Park, Florida--(Newsfile Corp. - August 13, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies, biologics, and advanced clinical services, today announced financial results for the second quarter ended June 30, 2026, as reported in its Form 10-Q filed with the Securities and Exchange Commission. Inline Viewer: ADIA NUTRITION, INC.
View source ↗
Insider trading
Open-market buys and sells by ADIA officers and directors.
- Bought
- $740
- Sold
- —
2 trades
0 trades
- Pivx Solutions, Inc.bought
- Pivx Solutions, Inc.bought
Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ADIA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.